Skip to main content
padlock icon - secure page this page is secure

Squalene as Novel Food Factor

Buy Article:

$68.00 + tax (Refund Policy)

Currently, health beneficial roles of natural products attract much attention and diverse functional ingredients have been extensively studied their preventive effect in many diseases such as cardiovascular diseases and cancer. Squalene is one of those examples. It distributes in nature from plant to animal but extraordinarily concentrated in the liver of certain species of shark (Squalidae family) as it was first identified as a healing substance in the shark liver oil. It is now well-known that squalene is the physiological substance functioning in animal as the precursor of cholesterol biosynthesis. On the other hand, it has long history of using as an attractive resource for functional food, supplement or even pharmaceutics because it has unique physical property and wide variety of physiological functions such as anticancer and anti-hyper cholesterolemia. The antioxidant and oxygen carrying properties of squalene predicts its potential in preventing cardiovascular disease. We reviewed recent progress in functional studies of squalene both in vitro and in vivo models.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 3-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitroso urea; Alanine aminotransferase; Aspartate aminotransferase; Catalase; Creatine phosphokinase; GENOTOXICITY; Gas liquid chromatography; Glutathione peroxidase; Glutathione reductase; Glutathione-S-transferase; High density lipoprotein; Lactate dehydrogenase; Leptin; Low density lipoprotein; Reactive oxygen species; Squalene; Superoxide dismutase; Total reduced glutathione; amelioration; antagonistic actions; anticarcinogenic; antilipidemic; antioxidant; antioxidant potential; antitumor activity; autopsy; b-Hydroxy-b -methylglutaryl CoA reductase; bilirubin; cardioprotective function; cardiovascular diseases; cathespin D; cyclophosphamide; cytoprotective agents; epigenetic control; farnesyl pyrophosphate (FPP); genotoxicity prevention; hemolysate; hypercholesterolemia; lymphocytic leukemia; lysosomal fractions; mutagenecity; myocardial infraction; oncogene; phytochemicals; quality of life

Document Type: Research Article

Publication date: December 1, 2010

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more